Georgia on March 29 to April 3, 2019 by medical student Ross Mudgway and Sharon Lum, medical director of the Breast Health Center at Loma Linda University, on the survival rate of patients with human epidermal growth factor receptor two (HER2)-positive, stage IV breast cancer who underwent ...
Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. We conducted a ... Burstein,J H. - 《Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology》 被引量: 1162发表: 2003年 ...
Recent trial-level meta-analyses have established disease-free survival (DFS) as a valid surrogate for overall survival (OS) in human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC), irrespective of disease stage, and in early-stage hormone receptor-positive (HR+)/HER2...
unfortunately. I see one patient a week with a node-negative, ER-positive breast cancer. I saw one yesterday; grade 1, but HER2, ratio 2.1, 2+ equivocal on IHC. And so, the discussion has to be that the standard of care
A tendency of decreasing breast cancer-specific survival with younger age was attributed to increases in hormone receptor-positive high-grade cancer26,27. However, the possible reasons for the observed trends in younger age groups are manyfold, and may also reflect changes concerning modifiable risk...
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH stud... A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with ...
Yao Wong,Akshara Singareeka Raghavendra,Christos Hatzis,et al.Long-term survival of de novo stage IV human epidermal growth factor receptor 2(HER2)-positive breast cancers treated with HER2 targeted therapy [C].2017ASCO annual meeting,1021 Poster Session (Board #13)....
HER2+ subtypes are also characterised by their aggressiveness and a high risk of recurrence, but targeted therapy administered in a timely manner can significantly improve patient survival [30]. The characteristics of different BC molecular subtypes, such as progression rate, radiologic appearance ...
The addition of intravenous trastuzumab to first-line chemotherapy improved the time to disease progression, objective response rate, duration of response, and overall survival in randomised, multicentre trials in women with HER2-positive metastatic breast cancer. As such, trastuzumab has become the ...
Based on RECIST v1.1 criteria, the confirmed ORR stood at 77.1% (95% CI: 59.9% to 89.6%), with a disease control rate of 97.1% (95% CI: 85.1% to 99.9%). The median progression-free survival was 10.38 months (95% CI: 7.79 to 12.45). Patient quality of life had a transient ...